查看購物車
  • Simplified Chinese
  • English
抗體藥物偶聯物市場規模及預測 2021-2031、全球及地區佔有率、趨勢及成長機會分析報告涵蓋範圍：按技術、應用、目標、配銷通路和地理分類
市場調查報告書
商品編碼
1646513

抗體藥物偶聯物市場規模及預測 2021-2031、全球及地區佔有率、趨勢及成長機會分析報告涵蓋範圍：按技術、應用、目標、配銷通路和地理分類

Antibody Drug Conjugates Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Target, Distribution Channel, and Geography
出版日期: | 出版商: The Insight Partners | 英文 286 Pages | 訂單完成後即時交付

價格

抗體藥物偶聯物市場規模預計將從 2023 年的 81 億美元增至 2031 年的 380.7 億美元；預計 2023 年至 2031 年期間市場複合年成長率為 21.3%。推動市場成長的主要因素包括主要參與者的策略性投資和核准產品供應的增加。此外，在預測期內，新適應症的擴展可能會促進市場發展。然而，製造方面的挑戰是市場阻礙因素之一。

抗體-藥物偶聯物（抗體-藥物偶聯物）市場主要參與者之間的合併、收購、夥伴關係和合作等策略投資對其成長和發展有重大影響。這些策略使公司能夠匯集資源、共享專業知識並利用互補優勢來增強其在快速變化的環境中競爭優勢。在尋求創新癌症療法的過程中，抗體-藥物偶聯物因其能夠選擇性地靶向和破壞癌細胞，同時保護健康組織，從而最大限度地減少副作用的能力而受到關注。因此，大型製藥和生物技術公司擴大建立策略聯盟，以加速抗體-藥物偶聯物的開發和商業化。

隨著市場競爭日益激烈，各公司尋求收購或合併其他擁有有前景的抗體藥物偶聯技術或候選藥物的公司。例如，大型製藥公司收購專門從事抗體藥物偶聯物開發的小型生技公司，以便將先進技術快速融入其現有產品線。此類收購有助於收購公司增強其產品組合，並獲得可提高其治療功效和安全性的新型連接技術、有效載荷和標靶機制。 2024 年 10 月，GlycoMimetics, Inc. 與 Crescent Biopharma, Inc. 達成收購協議，後者是一家私營生物技術公司，正在推動用於治療實體腫瘤的腫瘤治療藥物研發。交易完成後，該公司計劃以Crescent Biopharma, Inc. 的名義運作。設計和開發下一代抗體-藥物偶聯物。 2024 年 9 月，致力於開發下一代抗體藥物偶聯物的瑞士腫瘤學和生物技術公司 Araris Biotech AG 宣布與 Innate Pharma 達成協議。根據協議，Innate 將向 Araris 轉讓與其轉谷氨醯胺酶結合技術相關的專利組合。

抗體-藥物偶聯物市場的競爭格局特徵是主要參與者積極參與策略投資。這種活力鼓勵企業創新和改進，努力實現產品差異化並在市場上確立領導地位。資本湧入腫瘤學領域吸引了新進入者，從而形成了一個更活躍的生態系統，鼓勵創新想法。透過合併、收購、合作夥伴關係和合作進行的策略性投資在推動抗體-藥物偶聯物市場的成長方面發揮關鍵作用。這些投資透過增強產品組合、改進製造流程和促進創新來創造協同環境，以推動有效和有針對性的癌症治療方法的發展。

比較公司分析根據產品組合（產品滿意度、產品特性和可用性）、近期市場發展（併購、新產品發布和增強、投資和融資、獎勵、協議、合作）對抗體藥物偶聯物市場進行評估和分類、合作夥伴關係、認可和擴張）以及地理存在，有助於更好地決策和了解競爭格局。該報告深入探討了全球抗體藥物偶聯物市場領先供應商的最新重要發展和創新。主要市場參與者包括ADC Therapeutics SA、輝瑞公司、羅氏公司、第一三共株式會社、葛蘭素史克公司、吉利德科學公司、阿斯特捷利康公司、安斯泰來製藥公司、RemeGen 有限公司、武田製藥有限公司、默克集團、強生公司、百時美施貴寶公司、BioNTech SE、艾伯維公司。

根據技術，抗體藥物偶聯物市場分為可裂解接頭和不可裂解接頭。 2023 年，可裂解連接體佔據了市場的最大佔有率。根據應用，抗體藥物偶聯物市場分為血癌、腦癌、乳癌、卵巢癌、肺癌等。 2023 年，乳癌領域佔據了最大的市場。

抗體藥物偶聯物市場的公司採用了各種有機和無機策略。有機策略主要包括產品發布和產品批准。市場上見證的無機成長策略是收購、合作和夥伴關係。這些成長策略使市場參與者能夠擴大業務、增強地理影響力，同時促進整體市場的成長。此外，收購和合作等策略有助於加強他們的客戶群並擴展他們的產品組合。以下列出了抗體藥物偶聯物市場主要參與者的一些重要發展。

2024年11月，阿斯特捷利康在新加坡建造了一座價值15億美元的抗體藥物偶聯物（ADC）生產工廠，將改善其ADC產品組合的全球供應。 ADC 是一種先進的治療方法，旨在利用標靶抗體將強效抗癌劑直接輸送到癌細胞。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 發育基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：抗體藥物偶聯物市場格局

  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表
    • 核准產品清單
    • 管道分析
    • 監管指南

第 5 章：抗體藥物偶聯物市場 - 關鍵市場動態

  • 抗體藥物偶聯物市場 - 關鍵市場動態
  • 市場促進因素
    • 關鍵參與者的策略投資
    • 增加核准產品的供應量
  • 市場限制
    • 製造挑戰
  • 市場機會
    • 拓展新適應症
  • 未來趨勢
    • 擴大臨床試驗管道
  • 促進因素和限制因素的影響：

第 6 章：抗體藥物偶聯物市場 - 全球市場分析

  • 抗體藥物偶聯物市場收入，2021-2031 年
  • 概述
  • 抗體藥物偶聯物市場預測分析

第 7 章：抗體藥物偶聯物市場分析 - 依技術

  • 可裂解接頭
  • 不可切割接頭

第 8 章：抗體藥物偶聯物市場分析 - 按應用

  • 血癌
  • 腦癌
  • 乳癌
  • 卵巢癌
  • 肺癌
  • 其他

第 9 章：抗體藥物偶聯物市場分析 - 按目標

  • HER2
  • CD22
  • CD30
  • 其他

第 10 章：抗體藥物偶聯物市場分析 - 按配銷通路

  • 零售藥局
  • 醫院藥房
  • 網路藥局

第 11 章：抗體藥物偶聯物市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：競爭格局

    • 熱圖分析
    • 公司股票分析：

第 13 章：產業格局

  • 概述
  • 抗體藥物偶聯物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 14 章：公司簡介

  • ADC Therapeutics SA
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Co Ltd
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Merck KGaA
  • Johnson & Johnson
  • Bristol-Myers Squibb Co
  • BioNTech SE
  • AbbVie Inc

第 15 章：附錄

Product Code: TIPRE00003494

The antibody drug conjugates market is expected to reach US$ 38.07 billion by 2031 from US$ 8.10 billion in 2023; the market is estimated to grow at a CAGR of 21.3% during 2023-2031. Major factors driving the market growth include strategic investments by key players and increase in availability of approved products. Further, expansion into new indications is likely to boost the market during the forecast period. However, manufacturing challenges are among the market deterrents.

Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates (antibody-drug conjugates) market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.

As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. In September 2024, Araris Biotech AG, a Swiss oncology and biotechnology company involved in developing next-generation antibody-drug conjugates, announced making an agreement with Innate Pharma. Under the agreement, Innate would assign Araris a portfolio of patents related to its transglutaminase conjugation technology.

The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.

The comparative company analysis evaluates and categorizes the antibody drug conjugates market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Antibody Drug Conjugates Market. The key market players are ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Co Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Co, BioNTech SE, AbbVie Inc.

Based on technology, the antibody drug conjugates market is segmented into cleavable linker and non-cleavable linker. In 2023, the cleavable linker segment held the largest share of the market. Based on application, the antibody drug conjugates market is segmented into blood cancer, brain cancer, breast cancer, ovarian cancer, lung cancer and others. In 2023, the breast cancer segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the antibody drug conjugates market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the antibody drug conjugates market are listed below.

In November 2024, AstraZeneca constructed a US$ 1.5 billion manufacturing facility in Singapore dedicated to antibody drug conjugates (ADCs), which will improve the global supply of its ADC portfolio. ADCs are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Antibody Drug Conjugates Market Landscape

  • 4.1 PEST Analysis
  • 4.2 Ecosystem Analysis
    • 4.2.1 List of Vendors in the Value Chain
    • 4.2.2 List of Approved Products
    • 4.2.3 Pipeline Analysis
    • 4.2.4 Regulatory Guidelines

5. Antibody Drug Conjugates Market - Key Market Dynamics

  • 5.1 Antibody Drug Conjugates Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Strategic Investments by Key Players
    • 5.2.2 Increase in Availability of Approved Products
  • 5.3 Market Restraints
    • 5.3.1 Manufacturing Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Expansion into New Indications
  • 5.5 Future Trends
    • 5.5.1 Expanding Clinical Trial Pipeline
  • 5.6 Impact of Drivers and Restraints:

6. Antibody Drug Conjugates Market - Global Market Analysis

  • 6.1 Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
  • 6.2 Overview
  • 6.3 Antibody Drug Conjugates Market Forecast Analysis

7. Antibody Drug Conjugates Market Analysis - by Technology

  • 7.1 Cleavable Linker
    • 7.1.1 Overview
    • 7.1.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Non-cleavable Linker
    • 7.2.1 Overview
    • 7.2.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibody Drug Conjugates Market Analysis - by Application

  • 8.1 Blood Cancer
    • 8.1.1 Overview
    • 8.1.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Brain Cancer
    • 8.2.1 Overview
    • 8.2.2 Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Breast Cancer
    • 8.3.1 Overview
    • 8.3.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Ovarian Cancer
    • 8.4.1 Overview
    • 8.4.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Lung Cancer
    • 8.5.1 Overview
    • 8.5.2 Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibody Drug Conjugates Market Analysis - by Target

  • 9.1 HER2
    • 9.1.1 Overview
    • 9.1.2 HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 CD22
    • 9.2.1 Overview
    • 9.2.2 CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 CD30
    • 9.3.1 Overview
    • 9.3.2 CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibody Drug Conjugates Market Analysis - by Distribution Channel

  • 10.1 Retail Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Hospital Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibody Drug Conjugates Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Antibody Drug Conjugates Market Overview
    • 11.2.2 North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.2.3.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.2.4 North America: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.2.4.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.2.5 North America: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.2.5.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.2.6 North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.6.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.2.7 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.2 United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 United States: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.2.2 United States: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.2.3 United States: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.2.4 United States: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.7.3 Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Canada: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.3.2 Canada: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.3.3 Canada: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.3.4 Canada: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.2.7.4 Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.4.1 Mexico: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.2.7.4.2 Mexico: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.2.7.4.3 Mexico: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.2.7.4.4 Mexico: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.3 Europe
    • 11.3.1 Europe Antibody Drug Conjugates Market Overview
    • 11.3.2 Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.3.3.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.3.4 Europe: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.3.4.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.3.5 Europe: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.3.5.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.3.6 Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.6.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.3.7 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.2 United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.2.2 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.2.3 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.2.4 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.3 Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 Germany: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.3.2 Germany: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.3.3 Germany: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.3.4 Germany: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.4 France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 France: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.4.2 France: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.4.3 France: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.4.4 France: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.5 Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 Italy: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.5.2 Italy: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.5.3 Italy: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.5.4 Italy: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.6 Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Spain: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.6.2 Spain: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.6.3 Spain: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.6.4 Spain: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.3.7.7 Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.7.1 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.3.7.7.2 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.3.7.7.3 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.3.7.7.4 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Antibody Drug Conjugates Market Overview
    • 11.4.2 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.4.3.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.4.4 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.4.4.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.4.5 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.4.5.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.4.6 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.6.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.4.7 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.2 China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.2.1 China: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.2.2 China: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.2.3 China: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.2.4 China: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.3 Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.3.1 Japan: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.3.2 Japan: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.3.3 Japan: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.3.4 Japan: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.4 India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.4.1 India: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.4.2 India: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.4.3 India: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.4.4 India: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.5 Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.5.1 Australia: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.5.2 Australia: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.5.3 Australia: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.5.4 Australia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.6 South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.6.1 South Korea: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.6.2 South Korea: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.6.3 South Korea: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.6.4 South Korea: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.4.7.7 Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.7.1 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.4.7.7.2 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.4.7.7.3 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.4.7.7.4 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Antibody Drug Conjugates Market Overview
    • 11.5.2 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.5.3.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.5.4 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.5.4.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.5.5 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.5.5.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.5.6 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.6.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.5.7 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.2 South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.2.1 South Africa: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.2.2 South Africa: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.2.3 South Africa: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.2.4 South Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.3 Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.3.1 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.3.2 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.3.3 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.3.4 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.4 United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.4.1 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.4.2 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.4.3 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.4.4 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.5.7.5 Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.5.1 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.5.7.5.2 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.5.7.5.3 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.5.7.5.4 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  • 11.6 South and Central America
    • 11.6.1 South and Central America Antibody Drug Conjugates Market Overview
    • 11.6.2 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.6.3 South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
      • 11.6.3.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
    • 11.6.4 South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
      • 11.6.4.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
    • 11.6.5 South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
      • 11.6.5.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
    • 11.6.6 South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.6.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
    • 11.6.7 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.2 Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.2.1 Brazil: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.2.2 Brazil: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.2.3 Brazil: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.2.4 Brazil: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.7.3 Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.3.1 Argentina: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.3.2 Argentina: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.3.3 Argentina: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.3.4 Argentina: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
      • 11.6.7.4 Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.4.1 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
        • 11.6.7.4.2 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
        • 11.6.7.4.3 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
        • 11.6.7.4.4 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel

12. Competitive Landscape

    • 12.1.1 Heat Map Analysis
    • 12.1.2 Company Share Analysis:

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Antibody Drug Conjugates Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 ADC Therapeutics SA
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 F. Hoffmann-La Roche Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Daiichi Sankyo Co Ltd
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Financial Overview
    • 14.4.4 SWOT Analysis
    • 14.4.5 Key Developments
  • 14.5 GSK Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Financial Overview
    • 14.5.4 SWOT Analysis
    • 14.5.5 Key Developments
  • 14.6 Gilead Sciences Inc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AstraZeneca Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Astellas Pharma Inc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 RemeGen Co Ltd
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Financial Overview
    • 14.9.4 SWOT Analysis
    • 14.9.5 Key Developments
  • 14.10 Takeda Pharmaceutical Co Ltd
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 Merck KGaA
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Products and Services
    • 14.11.4 Financial Overview
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments
  • 14.12 Johnson & Johnson
    • 14.12.1 Key Facts
    • 14.12.2 Business Description
    • 14.12.3 Products and Services
    • 14.12.4 Financial Overview
    • 14.12.5 SWOT Analysis
    • 14.12.6 Key Developments
  • 14.13 Bristol-Myers Squibb Co
    • 14.13.1 Key Facts
    • 14.13.2 Business Description
    • 14.13.3 Products and Services
    • 14.13.4 Financial Overview
    • 14.13.5 SWOT Analysis
    • 14.13.6 Key Developments
  • 14.14 BioNTech SE
    • 14.14.1 Key Facts
    • 14.14.2 Business Description
    • 14.14.3 Products and Services
    • 14.14.4 Financial Overview
    • 14.14.5 SWOT Analysis
    • 14.14.6 Key Developments
  • 14.15 AbbVie Inc
    • 14.15.1 Key Facts
    • 14.15.2 Business Description
    • 14.15.3 Products and Services
    • 14.15.4 Financial Overview
    • 14.15.5 SWOT Analysis
    • 14.15.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Antibody Drug Conjugates Market Segmentation
  • Table 2. List of Vendors
  • Table 3. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 4. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 5. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 6. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Target
  • Table 7. Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 8. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 9. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 10. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 11. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 12. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 13. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 14. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 15. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 16. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 17. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 18. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 19. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 20. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 21. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 22. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 23. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 24. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 25. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 26. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 27. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 28. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 29. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 30. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 31. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 32. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 33. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 34. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 35. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 36. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 37. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 38. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 39. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 40. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 41. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 42. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 43. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 44. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 45. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 46. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 47. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 48. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 49. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 50. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 51. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 52. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 53. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 54. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 55. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 56. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 57. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 58. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 59. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 60. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 61. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 62. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 63. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 64. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 65. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 66. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 67. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 68. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 69. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 70. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 71. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 72. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 73. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 74. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 75. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 76. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 77. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 78. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 79. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 80. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 81. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 82. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 83. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 84. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 85. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 86. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 87. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 88. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 89. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 90. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 91. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 92. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 93. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 94. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 95. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 96. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 97. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 98. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 99. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 100. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 101. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 102. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 103. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 104. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 105. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 106. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 107. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 108. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 109. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 110. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 111. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 112. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 113. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 114. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 115. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 116. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 117. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 118. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 119. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Target
  • Table 120. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 121. Company Share Analysis
  • Table 122. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 123. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. Antibody Drug Conjugates Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
  • Figure 5. Antibody Drug Conjugates Market Share (%) - by Technology (2023 and 2031)
  • Figure 6. Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Antibody Drug Conjugates Market Share (%) - by Application (2023 and 2031)
  • Figure 9. Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Antibody Drug Conjugates Market Share (%) - by Target (2023 and 2031)
  • Figure 16. HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Antibody Drug Conjugates Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 21. Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Antibody Drug Conjugates Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 25. North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. North America: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 27. North America: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 28. North America: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 29. North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 30. North America: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 31. United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Europe: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 36. Europe: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 37. Europe: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 38. Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 39. Europe: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 40. United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 48. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 49. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 50. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 51. Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 52. China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 60. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 61. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 62. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 63. Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 64. South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 68. South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 69. South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology (2023 and 2031)
  • Figure 70. South and Central America: Antibody Drug Conjugates Market Breakdown, by Application (2023 and 2031)
  • Figure 71. South and Central America: Antibody Drug Conjugates Market Breakdown, by Target (2023 and 2031)
  • Figure 72. South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel (2023 and 2031)
  • Figure 73. South and Central America: Antibody Drug Conjugates Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 74. Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 75. Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 76. Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 77. Growth Strategies in Antibody Drug Conjugates Market